Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review

Arthritis Res Ther. 2018 Oct 12;20(1):229. doi: 10.1186/s13075-018-1725-6.

Abstract

Tumor necrosis factor (TNF) is a pleiotropic cytokine involved in many aspects of immune regulation. Anti-TNF biological therapy has been considered a breakthrough in the treatment of chronic autoimmune diseases, such as rheumatoid arthritis (RA). In this review, because of the major involvement of T cells in RA pathogenesis, we discuss the effects of anti-TNF biotherapy on T-cell responses in RA patients. We also outline the potential fields for future research in the area of anti-TNF therapy in RA.This could be useful to better understand the therapeutic efficiency and the side effects that are encountered in RA patients. Better targeting of T cells in RA could help set more specific anti-TNF strategies and develop prediction tools for response.

Keywords: Anti-TNF; Biotherapy; Rheumatoid arthritis; T-cell.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / metabolism*
  • Biological Products / pharmacology
  • Biological Products / therapeutic use*
  • Biological Therapy / methods
  • Biological Therapy / trends
  • Humans
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / physiology*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Antirheumatic Agents
  • Biological Products
  • Tumor Necrosis Factor-alpha